Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 4/20 | 0.34 |
| ▸ | CFTR | P13569 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | RAF1 | P04049 | 2/20 | 0.30 |
| ▸ | BRAF | P15056 | 2/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26527316 | 0.94 | ADORA2A (0.34) | GABRA5CFTRADORA2AADORA2BADORA1 | |
| SCHEMBL26527315 | 0.93 | GABRA5 (0.33) | GABRA5CFTR | |
| SCHEMBL26527318 | 0.93 | CFTR (0.32) | GABRA5CFTRPOLBKMT2A | |
| SCHEMBL26545544 | 0.93 | CFTR (0.34) | GABRA5CFTRRAF1BRAF | |
| SCHEMBL26527274 | 0.93 | GABRA5 (0.32) | GABRA5CFTRRAF1BRAF | |
| SCHEMBL26527278 | 0.93 | GABRA5 (0.32) | GABRA5CFTR | |
| SCHEMBL24986117 | 0.92 | GABRA5 (0.34) | GABRA5CFTRPOLBKMT2ANR3C1 | |
| SCHEMBL24986121 | 0.92 | GABRA5 (0.34) | GABRA5CFTRPOLBKMT2ANR3C1 | |
| SCHEMBL26527287 | 0.92 | CFTR (0.32) | GABRA5CFTR | |
| SCHEMBL25115960 | 0.92 | GABRA5 (0.33) | GABRA5CFTRPOLBKMT2ARAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | GABRA5 3773/4885CFTR 283/4885POLB 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.